MX370890B - Composición que comprende sulfato de salbutamol. - Google Patents
Composición que comprende sulfato de salbutamol.Info
- Publication number
- MX370890B MX370890B MX2015014513A MX2015014513A MX370890B MX 370890 B MX370890 B MX 370890B MX 2015014513 A MX2015014513 A MX 2015014513A MX 2015014513 A MX2015014513 A MX 2015014513A MX 370890 B MX370890 B MX 370890B
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- salbutamol sulphate
- component
- pharmaceutical composition
- surfactant
- Prior art date
Links
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 abstract 2
- 229940071648 metered dose inhaler Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
- 229940051271 1,1-difluoroethane Drugs 0.000 abstract 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005642 Oleic acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe una composición farmacéutica que es adecuada para liberar de un recipiente presurizado. La composición está preferiblemente libre de excipientes polares y comprende: (a) un componente propelente que consiste esencialmente de 1,1-difluoroetano (R-152); (b) un componente tensoactivo que comprende al menos un compuesto tensoactivo diferente al ácido tensoactivo; (c) un componente tensoactivo que consiste de sulfato de salbutamol. La composición farmacéutica puede ser liberada usando un inhalador de dosis medida (MDI).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1306984.4A GB201306984D0 (en) | 2013-04-17 | 2013-04-17 | Composition |
| PCT/GB2014/051221 WO2014170689A1 (en) | 2013-04-17 | 2014-04-17 | Composition comprising salbutamol sulphate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015014513A MX2015014513A (es) | 2016-02-09 |
| MX370890B true MX370890B (es) | 2020-01-09 |
Family
ID=48537398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015014513A MX370890B (es) | 2013-04-17 | 2014-04-17 | Composición que comprende sulfato de salbutamol. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10959965B2 (es) |
| EP (1) | EP2986283B1 (es) |
| JP (1) | JP6085716B2 (es) |
| CN (1) | CN105120850B (es) |
| AU (1) | AU2014255466B2 (es) |
| BR (1) | BR112015026053B1 (es) |
| CA (1) | CA2909431C (es) |
| ES (1) | ES2632814T3 (es) |
| GB (1) | GB201306984D0 (es) |
| MX (1) | MX370890B (es) |
| WO (1) | WO2014170689A1 (es) |
| ZA (1) | ZA201507717B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017093758A1 (en) | 2015-12-04 | 2017-06-08 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| ES2949975T3 (es) * | 2016-09-19 | 2023-10-04 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende indacaterol |
| US10888546B2 (en) | 2016-09-19 | 2021-01-12 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| JP6781832B2 (ja) | 2016-09-19 | 2020-11-04 | メキシケム フロー エセ・ア・デ・セ・ヴェ | 医薬組成物 |
| GB2554089A (en) * | 2016-09-19 | 2018-03-28 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| GB2573297A (en) * | 2018-04-30 | 2019-11-06 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| FR3130554B1 (fr) | 2021-12-20 | 2024-10-18 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
| FR3137830A1 (fr) | 2022-07-13 | 2024-01-19 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
| US12383516B1 (en) | 2025-01-06 | 2025-08-12 | Amphastar Pharmaceuticals, Inc. | Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5252720A (en) | 1989-03-06 | 1993-10-12 | Board Of Regents, The University Of Texas System | Metal complexes of water soluble texaphyrins |
| GB9001019D0 (en) * | 1990-01-17 | 1990-03-14 | Euro Celtique Sa | Pharmaceutical aerosol |
| IL97065A (en) * | 1990-02-02 | 1994-01-25 | Fisons Plc | Repellent preparations for aerosol |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| AU675633B2 (en) | 1991-12-18 | 1997-02-13 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| PT731688E (pt) * | 1993-12-02 | 2003-07-31 | Abbott Lab | Formulacoes de farmacos em aerossol para utilizacao com propulsores sem cfc |
| CN1088580C (zh) | 1994-12-22 | 2002-08-07 | 阿斯特拉公司 | 气溶胶药物制剂 |
| SK284448B6 (sk) * | 1995-04-14 | 2005-04-01 | Glaxo Wellcome Inc. | Merací dávkovací inhalátor |
| ATE239447T1 (de) | 1997-09-29 | 2003-05-15 | Inhale Therapeutic Syst | In verneblern verwendbare, stabilisierte zubereitungen |
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
| FR2779649B1 (fr) * | 1998-06-15 | 2001-04-13 | Oreal | Composition pulverulente chauffante solide a hydrater pour le soin ou le nettoyage de la peau |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| AU749697B2 (en) | 1998-08-04 | 2002-07-04 | Jagotec Ag | Medicinal aerosol formulations |
| GB2392915B (en) | 1999-09-11 | 2004-04-28 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
| US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| CN1144582C (zh) | 2000-11-28 | 2004-04-07 | 中国药科大学 | 治疗呼吸系统疾病的无氟里昂药用气雾剂 |
| CN1216600C (zh) | 2002-04-24 | 2005-08-31 | 信谊药厂 | 盐酸左旋沙丁胺醇气雾剂及制备工艺 |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0323685D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2006004646A1 (en) | 2004-06-28 | 2006-01-12 | Nektar Therapeutics | Aerosol formulation comprising nicotine salt |
| WO2007020204A2 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
| DE102006053374A1 (de) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz |
| DE102006017320A1 (de) * | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel |
| JP2012507574A (ja) * | 2008-11-04 | 2012-03-29 | シプラ・リミテッド | 医薬エアロゾル組成物 |
| GB0915106D0 (en) | 2009-08-28 | 2009-10-07 | Glaxo Group Ltd | Process |
| GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
| GB201117621D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| US20130104881A1 (en) * | 2011-10-31 | 2013-05-02 | Laboratorio Pablo Cassara S.R.L. | Stabilized Metered Dose Inhaler |
-
2013
- 2013-04-17 GB GBGB1306984.4A patent/GB201306984D0/en not_active Ceased
-
2014
- 2014-04-17 EP EP14726400.6A patent/EP2986283B1/en active Active
- 2014-04-17 BR BR112015026053-5A patent/BR112015026053B1/pt active IP Right Grant
- 2014-04-17 CA CA2909431A patent/CA2909431C/en active Active
- 2014-04-17 AU AU2014255466A patent/AU2014255466B2/en active Active
- 2014-04-17 WO PCT/GB2014/051221 patent/WO2014170689A1/en not_active Ceased
- 2014-04-17 US US14/784,798 patent/US10959965B2/en active Active
- 2014-04-17 ES ES14726400.6T patent/ES2632814T3/es active Active
- 2014-04-17 CN CN201480021833.4A patent/CN105120850B/zh active Active
- 2014-04-17 JP JP2016508244A patent/JP6085716B2/ja active Active
- 2014-04-17 MX MX2015014513A patent/MX370890B/es active IP Right Grant
-
2015
- 2015-10-15 ZA ZA2015/07717A patent/ZA201507717B/en unknown
-
2020
- 2020-02-05 US US16/782,143 patent/US20200179310A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6085716B2 (ja) | 2017-02-22 |
| GB201306984D0 (en) | 2013-05-29 |
| US20160058714A1 (en) | 2016-03-03 |
| WO2014170689A1 (en) | 2014-10-23 |
| MX2015014513A (es) | 2016-02-09 |
| EP2986283A1 (en) | 2016-02-24 |
| CA2909431C (en) | 2017-10-10 |
| AU2014255466A1 (en) | 2015-11-05 |
| AU2014255466B2 (en) | 2016-07-07 |
| BR112015026053A2 (pt) | 2017-07-25 |
| EP2986283B1 (en) | 2017-05-17 |
| US20200179310A1 (en) | 2020-06-11 |
| ZA201507717B (en) | 2023-12-20 |
| JP2016518364A (ja) | 2016-06-23 |
| CN105120850A (zh) | 2015-12-02 |
| US10959965B2 (en) | 2021-03-30 |
| BR112015026053A8 (pt) | 2020-01-14 |
| BR112015026053B1 (pt) | 2023-01-10 |
| ES2632814T3 (es) | 2017-09-15 |
| CA2909431A1 (en) | 2014-10-23 |
| CN105120850B (zh) | 2018-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014004279A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| MX2015014513A (es) | Composicion que comprende sulfato de salbutamol. | |
| MX2020012810A (es) | Formulación de nicotina. | |
| MX2014004364A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| MX2013012975A (es) | Composiciones farmaceuticas. | |
| EP4512394A3 (en) | Dosage forms and use thereof | |
| HK1221653A1 (zh) | 用於呼吸递送三种或更多种活性剂的组合物、方法和系统 | |
| WO2015054124A3 (en) | Dry powder inhaler | |
| WO2014064410A8 (en) | Pharmaceutical composition | |
| MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| ZA202007890B (en) | Stable pharmaceutical compositions for pressurized metered dose inhalers | |
| IN2014DN01619A (es) | ||
| MX2015015132A (es) | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. | |
| MX2021006751A (es) | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. | |
| WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| WO2014007770A3 (en) | Inhalation compositions comprising corticosteroid and sorbitol | |
| MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
| MX2015015150A (es) | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. | |
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| ZA202003904B (en) | Drug delivery system | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| WO2015195711A3 (en) | Method and devices for manufacturing and delivering of aerosolized formulations | |
| WO2015130963A3 (en) | Compositions and methods for administering insulin or insulin-like protein to the brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |